Zobrazeno 1 - 10
of 488
pro vyhledávání: '"Kiyohiko, Hatake"'
Autor:
Masahiro Yokoyama, Yoshiharu Kusano, Norihito Inoue, Noriko Nishimura, Yuko Mishima, Tomoyuki Nukada, Kiyohiko Hatake, Yasuhito Terui
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-11 (2021)
Abstract Background A classification tree was used to analyze background factors for granulocyte colony-stimulating factor (G-CSF) preparation selection for febrile neutropenia (FN) prophylaxis in Japanese patients with non-Hodgkin B-cell lymphoma re
Externí odkaz:
https://doaj.org/article/c104cb09f17a477da0b8915bcb699586
Autor:
Noriko Fukuhara, Dai Maruyama, Kiyohiko Hatake, Hirokazu Nagai, Shinichi Makita, Kenjiro Kamezaki, Toshiki Uchida, Shigeru Kusumoto, Junya Kuroda, Chisako Iriyama, Masamitsu Yanada, Norifumi Tsukamoto, Youko Suehiro, Hironobu Minami, Jose Garcia-Vargas, Barrett H. Childs, Masanobu Yasuda, Shigeo Masuda, Toshiaki Tsujino, Yui Terao, Kensei Tobinai
Publikováno v:
International Journal of Hematology. 117:100-109
The safety, efficacy, and pharmacokinetics of copanlisib were evaluated in this phase Ib/II study in Japanese patients with relapsed/refractory indolent non-Hodgkin lymphoma (NHL). The primary endpoint was safety at the recommended dose; efficacy end
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4066c0442811c43f0be110ee26201b49
https://doi.org/10.1007/s12185-022-03455-0
https://doi.org/10.1007/s12185-022-03455-0
Autor:
David MacDonald, Erik Vandendries, Joseph Boni, M. Luisa Paccagnella, Taro Ishibashi, Revathi Ananthakrishnan, Michael Crump, Andrew Davies, Kiyohiko Hatake, Kensei Tobinai, Michinori Ogura
Purpose: To evaluate the safety, preliminary efficacy, and pharmacokinetics of inotuzumab ozogamicin, an anti-CD22 antibody conjugated to calicheamicin, in combination with the immunochemotherapeutic regimen, rituximab, cyclophosphamide, vincristine,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::35943ae76940aafc27c3ef3e767c0255
https://doi.org/10.1158/1078-0432.c.6524378.v1
https://doi.org/10.1158/1078-0432.c.6524378.v1
Autor:
Kiyohiko Hatake, Kiyotsugu Kojima, Masahiro Yokoyama, Hiroaki Asai, Daisuke Ennishi, Suzuka Asai, Kengo Takeuchi, Yasuhito Terui, Yuko Matsumoto-Mishima, Natsuhiko Sugimura, Yuji Mishima
Supplementary Data from An Imaging-Based Rapid Evaluation Method for Complement-Dependent Cytotoxicity Discriminated Clinical Response to Rituximab-Containing Chemotherapy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::95b60b8d491aa301bdf35dec127985fb
https://doi.org/10.1158/1078-0432.22439626.v1
https://doi.org/10.1158/1078-0432.22439626.v1
Autor:
David MacDonald, Erik Vandendries, Joseph Boni, M. Luisa Paccagnella, Taro Ishibashi, Revathi Ananthakrishnan, Michael Crump, Andrew Davies, Kiyohiko Hatake, Kensei Tobinai, Michinori Ogura
Table S1. Dose Escalation of C (3 levels) or InO (2 levels) and Treatment Schedule Used to Determine the MTD Based on a Standard 3+3 Design; Table S2. AEs Leading to Permanent Discontinuation or Modification of the MTD
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::292287707d94f0bbbf44fee9335e0ac0
https://doi.org/10.1158/1078-0432.22460018
https://doi.org/10.1158/1078-0432.22460018
Autor:
David MacDonald, Erik Vandendries, Joseph Boni, M. Luisa Paccagnella, Taro Ishibashi, Revathi Ananthakrishnan, Michael Crump, Andrew Davies, Kiyohiko Hatake, Kensei Tobinai, Michinori Ogura
SUPPLEMENTARY METHODS
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::680c53c2e6aad14300222af7086c39cd
https://doi.org/10.1158/1078-0432.22460021
https://doi.org/10.1158/1078-0432.22460021
Autor:
Kiyohiko Hatake, Kiyotsugu Kojima, Masahiro Yokoyama, Hiroaki Asai, Daisuke Ennishi, Suzuka Asai, Kengo Takeuchi, Yasuhito Terui, Yuko Matsumoto-Mishima, Natsuhiko Sugimura, Yuji Mishima
Purpose: Rituximab has greatly improved the efficacy of chemotherapy regimens for CD20-positive non-Hodgkin's lymphoma. However, although several mechanisms of action of rituximab have been identified, the exact therapeutic functions of these mechani
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4360bd877c3fe2326dcae2361eb06986
https://doi.org/10.1158/1078-0432.c.6517063
https://doi.org/10.1158/1078-0432.c.6517063
Autor:
Kenji Yoshikawa, Yasuyuki Kakurai, Koji Kato, Kensei Tobinai, Tokuhito Sumitani, Kiyohiko Hatake, Shinji Shimizu, Junya Kanda, Koichi Akashi, Koji Izutsu, Kazuyuki Shimada, Natsuko Fukuda, Hideki Goto, Shinichi Makita, Hiroyuki Sumi, Nobuharu Fujii, Noriko Usui, Takanori Teshima
Publikováno v:
International Journal of Clinical Oncology
Background Axicabtagene ciloleucel (axi-cel) is an autologous chimeric antigen receptor T-cell based anti-CD19 therapy. The ZUMA-1 study, multicenter, single-arm, registrational Phase 1/2 study of axi-cel demonstrated high objective response rate in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8882d6f47d70f87fc25cdf5f5429458e
https://doi.org/10.1007/s10147-021-02033-4
https://doi.org/10.1007/s10147-021-02033-4
Autor:
Koji Kato, Nobuharu Fujii, Shinichi Makita, Hideki Goto, Junya Kanda, Kazuyuki Shimada, Koichi Akashi, Koji Izutsu, Takanori Teshima, Natsuko Fukuda, Tokuhito Sumitani, Shota Nakamura, Hiroyuki Sumi, Shinji Shimizu, Yasuyuki Kakurai, Kenji Yoshikawa, Kensei Tobinai, Noriko Usui, Kiyohiko Hatake
Publikováno v:
International journal of hematology.
Axicabtagene ciloleucel (axi-cel) is an autologous, CD19-targeting chimeric antigen receptor T‑cell therapy. We recently reported the 3-month follow-up results of a phase 2, multicenter, open‑label, single-arm study of axi-cel in Japanese patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b99f7ab4024b8638a8c9de70f38d8b0
https://pubmed.ncbi.nlm.nih.gov/36399286
https://pubmed.ncbi.nlm.nih.gov/36399286
Autor:
Akira Nishiyama, Satoshi Kidoguchi, Yuichiro Yano, Kiyohiko Hatake, Naoki Sugano, Takashi Yokoo, Gorou Tokudome
Publikováno v:
Hypertension. 77(1):16-27
application/pdf
Owing to aging populations, the prevalence of hypertension and associated cardiovascular events has been increasing worldwide. The morbidity and mortality due to cancer have also been increasing with aging populations. Several sm
Owing to aging populations, the prevalence of hypertension and associated cardiovascular events has been increasing worldwide. The morbidity and mortality due to cancer have also been increasing with aging populations. Several sm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c886e48c54cf6775b884bbf3de38b16
https://kagawa-u.repo.nii.ac.jp/records/11426
https://kagawa-u.repo.nii.ac.jp/records/11426